AI Bias Analysis
4 models · Takes ~15 seconds
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- Cardiovascular protection with GLP-1 receptor agonists may benefit patients undergoing certain transcatheter procedures, according to two observational studies. When used as an adjunct to transcatheter aortic valve replacement...
(MedPage Today) -- The investigational cell therapy deramiocel slowed upper limb functional decline in boys and young men with Duchenne muscular dystrophy, data from the phase III HOPE-3 trial showed. At 12 months, the mean percent change from...
(MedPage Today) -- Discussions at the American Academy of Dermatology annual meeting about chronic spontaneous urticaria (CSU) highlighted evolving skin-directed and immune-targeted therapies, but new research is challenging the view of CSU as...
Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.
